Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials

Next Previous
Trial Profile

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrutinib (Primary)
  • Indications B-cell leukaemia; B-cell lymphoma; Bladder cancer; Chronic lymphocytic leukaemia; Colon cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Gastric cancer; Graft-versus-host disease; Head and neck cancer; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Pancreatic cancer; Renal cancer; Solid tumours; Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Sponsors Pharmacyclics Switzerland

    • Most Recent Events

    • 21 Nov 2023 Planned number of patients changed from 500 to 600.
    • 10 Mar 2022 This trial has been completed in Belgium, according to European Clinical Trials Database record.
    • 12 Jul 2021 This trial has been completed in Germany, according to European Clinical Trials Database record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top